1830 related articles for article (PubMed ID: 25381986)
1. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
2. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
3. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
Punzi L; Lapadula G; Mathieu A
BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
[TBL] [Abstract][Full Text] [Related]
5. Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.
Bergman M; De G; Ganguli A; Signorovitch J; Bao Y
J Med Econ; 2015 Jan; 18(1):37-44. PubMed ID: 24841451
[TBL] [Abstract][Full Text] [Related]
6. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
Gabay C; Hasler P; Kyburz D; So A; Villiger P; von Kempis J; Walker U
Swiss Med Wkly; 2014; 144():w13950. PubMed ID: 24723273
[TBL] [Abstract][Full Text] [Related]
7. Potential use of TNF-α inhibitors in systemic sclerosis.
Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
9. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
Amano K
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139
[No Abstract] [Full Text] [Related]
11. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
12. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
13. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis.
Soubrier M; Jouanel P; Mathieu S; Poujol D; Claus D; Dubost JJ; Ristori JM
Joint Bone Spine; 2008 Jan; 75(1):22-4. PubMed ID: 17888710
[TBL] [Abstract][Full Text] [Related]
14. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
15. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
16. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF therapy.
Thalayasingam N; Isaacs JD
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):549-67. PubMed ID: 22137924
[TBL] [Abstract][Full Text] [Related]
18. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
19. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]